Skip to main content
News

Aranscia’s Houda Hachad Interviewed in the Journal of Clinical Pathways Regarding Recent FDA Safety Announcement

By March 26, 2025December 24th, 2025No Comments

Houda Hachad, PharmD, M.Res, was interviewed by the Journal of Clinical Pathways to discuss the FDA’s recent safety announcement regarding DPD deficiency testing.

“The FDA’s recent update stresses the importance of oncology care teams being aware of the risks of DPD deficiency, informing patients about these risks—including serious or life-threatening toxicities—before treatment, and discussing testing for the deficiency with their patients.” – Houda Hachad, PharmD, M.Res, Vice President Clinical Operations at Aranscia.

Click here to read more in the Journal of Clinical Pathways.

Leave a Reply